We propose that cardiac AAV9:PKP2 could be a beneficial gene therapy approach to reduce ventricular arrhythmias, slow down adverse right ventricular remodeling, improve heart function, and reduce mortality in ARVC patients with PKP2 mutations. This evidence concerns the gene PKP2 and Ventricular arrhythmia.